The U.S. Food and Drug Administration's (FDA's) accelerated approval program aims to get new drugs to patients as quickly as possible.

美国食品和药物管理局(FDA)的加速审批计划旨在尽快将新药送到患者手中。

Today, about 85 percent of accelerated approvals go to cancer drugs.

如今，大约85%的加速审批流向了抗癌药物。

The new study suggests most cancer drugs given accelerated approval do not improve or extend patients' lives within five years.

这项新的研究表明，大多数加速批准的抗癌药物在五年内不会改善或延长患者的生命。